Oral News and Research

RSS

Milk allergy successfully treated with Xolair

A latest study suggests that children with severe milk allergies may be able to rapidly overcome their sensitivities with the help of a biologic drug that helps to quiet an overly aggressive immune response. This is a small study still waiting to be proved in larger populations say researchers.

22 Mar 2011

Plackers provides Grind-No-More dental night protectors for taxpayers

Tax season is stressful for many Americans, and even the IRS's extension of this year's filing deadline to April 18 may not provide much relief.

22 Mar 2011

Objet demonstrates 3D printing solution benefits for digital dentistry at IDS

As digital dentistry becomes a standard production tool for many dental practices and laboratories, Objet Geometries Ltd. demonstrates the benefits of adding 3D printing to the workflow at IDS.

22 Mar 2011

Oral desensitization with omalizumab may treat milk allergy in children

Some 3 million children in the United States have some form of food allergy, ranging in severity from mild to life-threatening. Milk allergy is the most common, affecting 2.5 percent of children under age 3.

22 Mar 2011

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists and antagonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the presentation of positive clinical results from its randomized, placebo-controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis.

22 Mar 2011

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous Phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer.

21 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Hi-Tech Pharmacal acquires rights to Nystatin Oral suspension ANDA from Bausch + Lomb

Hi-Tech Pharmacal Co., Inc. announced that it has acquired the rights to the Abbreviated New Drug Application (ANDA) for Nystatin Oral suspension from Bausch + Lomb, the global eye health company for an undisclosed upfront payment and a future royalty.

21 Mar 2011

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

United Therapeutics Corporation announced today that enrollment in its FREEDOM-C(2) registration trial was completed on March 18, 2011.

21 Mar 2011

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher T. Nguyen will hold an oral presentation on a study titled "Mandibular Changes Produced by Skeletal Anchorage Assisted Orthopedic Traction."

21 Mar 2011

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher F. Cheni will hold an oral presentation on a research study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans (S. mutans) Biofilm Growth."

21 Mar 2011

Researcher to present study on validation of salivary-biomarkers for pSS patients

Saturday, March 19, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher A.N.M. Nazmul-Hossaini will hold an oral presentation on a study titled "Validation of Salivary-Biomarkers for Sj-gren's Syndrome Detection in US Population."

19 Mar 2011

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

ViroPharma Incorporated today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion at its plenary meeting in March 2011 recommending approval of a Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

19 Mar 2011

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Teva Pharmaceutical Industries Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of nomegestrol acetate in a 24/4 monophasic regimen.

18 Mar 2011

Science journal publishes CYTK preclinical cardiac myosin activation research results

Cytokinetics, Incorporated announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.

18 Mar 2011

Fuz expression critical for craniofacial and tooth development: Study

Today, during the 89th General Session & Exhibition of the International Association for Dental Research, held in conjunction with the 40th Annual Meeting of the American Association for Dental Research and the 35th Annual Meeting of the Canadian Association for Dental Research, lead researcher Z. Zhang will hold an oral presentation on a study titled "Fuz is Essential for Craniofacial and Tooth Development."

18 Mar 2011

China Botanic first quarter net sales increase 32.1% to $22.6 million

China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced financial results for the three months ended January 31, 2011, and reaffirmed guidance for its full fiscal year ending October 31, 2011.

17 Mar 2011

New lozenge clinical trial for dry mouth treatment

A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.

17 Mar 2011

Study suggests dissolvable tobacco products may cause mouth diseases

The first study to analyze the complex ingredients in the new genre of dissolvable tobacco products has concluded that these pop-into-the-mouth replacements for cigarettes in places where smoking is banned have the potential to cause mouth diseases and other problems.

17 Mar 2011

Cortex enters agreement with Biovail to regain AMPAKINE assets and rights

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., to regain the AMPAKINE® assets and rights related to respiratory depression.

16 Mar 2011

Oral News and Research

Milk allergy successfully treated with Xolair

Plackers provides Grind-No-More dental night protectors for taxpayers

Objet demonstrates 3D printing solution benefits for digital dentistry at IDS

Oral desensitization with omalizumab may treat milk allergy in children

Ventirx VTX-1463 positive clinical data against allergic rhinitis presented at AAAAI meeting

Intravenous Phenoxodiol-cisplatin combination well tolerated in platinum resistant ovarian cancer

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Hi-Tech Pharmacal acquires rights to Nystatin Oral suspension ANDA from Bausch + Lomb

United Therapeutics completes enrollment in FREEDOM-C(2) UT-15C study in pulmonary arterial hypertension

Study on mandibular changes produced by skeletal anchorage assisted orthopedic traction

Study on biodegradable tooth-binding micelles that inhibit Streptococcus mutans biofilm growth

Researcher to present study on validation of salivary-biomarkers for pSS patients

CHMP recommends approval of Centralized Marketing Authorization for Cinryze

EMA CHMP adopts positive opinion for Teva's NOMAC-E2 contraceptive pill

Science journal publishes CYTK preclinical cardiac myosin activation research results

Fuz expression critical for craniofacial and tooth development: Study

China Botanic first quarter net sales increase 32.1% to $22.6 million

New lozenge clinical trial for dry mouth treatment

Study suggests dissolvable tobacco products may cause mouth diseases

Cortex enters agreement with Biovail to regain AMPAKINE assets and rights

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News